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1 Summary 
All new technologies have an inherent risk, which is typically assessed alongside the development of 
applications of the technology. This is also the case for nanotechnology: a key concern in the case of 
engineered nanomaterials (ENMs) is that due to their very small size, NMs can reach areas such as the cell 
that are inaccessible to other materials, such as implants and drugs. As  a result of their large surface area, 
NMs may be more reactive than other larger materials. The large physical and chemical variability of NMs, 
and the fact that small changes can have large consequences, mean that there is insufficient data on which 
to make safety or risk assessments at present.  Thus, a widely supported scientific basis and sufficient high 
quality data upon which to base regulatory decisions are required urgently.  NanoImpactNet (NIN) can 
support the development and dissemination of such data.   
This report presents the outcome of the discussions of 60 experts in the field of safety assessment of 
manufactured NMs from academia, industry, government and non-profit organizations on some of the critical 
issues pertaining to the development of standard protocols and reference materials for assessment of the 
potential hazards associated with ENMs. It should be noted here that there was a separate NIN workshop on 
determining the best metrics for assessing NP safety, and that this workshop was directed specifically to how 
best to standardise testing protocols and develop reference materials for human health assessment. 
Some of the major conclusions drawn are listed below: 
 There is an urgent need for nanoparticle (NP) reference materials, not just for calibration of physical or 
chemical measurement methods, but also with carefully controlled surface properties for use as positive 
and negative controls for various biological impacts.  However, the validity of positive and negative 
control reference NMs was questioned, given the very significant batch-to-batch variability being 
reported for nanoparticles from all commercial and laboratory sources, not just in terms of their size but 
also in terms of their surface chemistries. 
 There is an urgent need to share details of protocols and best practice in the assessment of NM impacts 
on living systems. NIN offers an excellent platform to achieve this, and the project website should enable 
access to consortium members to help develop a structured approach to method development.  This has 
since been implemented within the NIN consortium. 
   It was recommended by the workshop participants that Organisation for Economic Co-operation and 
development (OECD) could / should provide templates for the type of data and supporting 
documentation that they require for the validation of protocols, and could also provide some training 
workshops in respect of the process necessary for development and validation of test methods and 
reference materials (e.g. biological positive and negative NP controls), such that these can be built into 
the protocols that are emerging within the scientific community.  NIN could facilitate this, via one of its 
training schools. 
   The need for another workshop on this topic closer to the end of the NIN project was highlighted during 
this workshop, as clearer consensus of the best practice, and recommendations regarding which 
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protocols for which end-point should be significantly advanced by then.  Additionally, a second workshop 
would give the consortium a chance to reflect on the role of NIN in facilitating the onward development 
and framing of the field in relation to human health impacts assessment.  
 
2 Background 
A nanomaterial is defined as a material that has one or more external dimensions in the nanoscale 
or which is nanostructured.1  A nano-object is defined as a discrete piece of material with one or more 
external dimensions in the nano-scale,2 and includes nanoparticles (NPs), which for the purpose of NIN 
reports are defined as “a sub-classification of ultrafine particles with lengths in two or three dimensions 
greater than 0.001 micrometre (1nm) and smaller than about 0.1micrometre (100nm) and which may or may 
not exhibit a size-related intensive property.”  The physical properties of materials at the nanoscale can differ 
from their bulk counterparts with large reactive surface area to volume ratios in NMs which may lead to size-
dependent effects.  
While there is extensive literature on the toxicity of ambient aerosol particles3 and a growing 
literature on the interactions of ENMs in biological systems,4 there remains considerable uncertainty 
regarding the potential toxicity of ENMs,5 and the approaches by which this is evaluated.6 Much of the 
current literature is clouded by issues such as chemical elution from NMs and aggregation of NMs into 
micron scale aggregates under the test conditions. As nanotechnology is developing very rapidly, with 
increasing levels of commercial production of EMNs, a series of standardized tests and protocols to assess 
the potential toxicity of these unique materials in biological systems is needed urgently.  
The lack of standard approaches and protocols in the assessment of potential NM hazards for 
human health is rapidly becoming a critical road block to the success of the entire field, and needs to be 
addressed urgently in order to ensure that the trust of the public, regulators and policy makers internationally 
is not lost irrevocably.  Issues such as the significant variability of surface properties between nominally 
“identical” particles from different batches (batch-to-batch variability); the tendency of NMs to aggregate 
under physiological conditions (ionic strength, pH and interaction with biomolecules all affect the dispersion 
characteristics and stability); differences in the cell passage number and degree of confluence of cells and a 
host of other factors all contribute to the enormous variability of biological impacts reported in the literature.  
This situation is untenable, as generating increasing amounts of data that are irreproducible and 
incomparable to other data sets will do little to address the multiple knowledge-gaps that have been 
identified, and may in fact result in the downfall of the nanotechnology revolution unless significant and 
concerted action is taken immediately. Thus, the need for standardized methodologies and experimental 
protocols that remove potential sources of irreproducibility in testing the potential toxicity of NMs, and for in-
depth characterization of NMs under the relevant experimental / test conditions, in order to ensure that 
comparisons can be made amongst in vitro investigations is evident. 
The European Network on the Health and Environmental Impact of Nanomaterials  
 
Lynch et al. - 6 / 22 - Standardization for hazard assessment of nanomaterials 
Other fields that have recently emerged have successfully applied the principles of round-robin 
approaches to validate themselves and their methodologies, such as the genomics and proteomics fields 
which operated via the Human Genome Organisation (HUGO) and Human Proteome Organisation (HUPO) 
respectively.  The pharmaceuticals industry has also successfully applied the round-robin approach to 
validate new drugs, driven via the European Medicines Agency (EMEA).  NIN, which is the largest European 
grouping of research, academic and other organisations in the field of nanosafety, is ideally placed to play a 
similar role for the issue of nanosafety, and the goals of this and the subsequent workshops and training 
schools are to identify approaches and areas where NIN can play a leading role in terms of clarifying many of 
the most pressing and outstanding issues that are acting as roadblocks to the successful and safe 
implementation of nanotechnology. 
 
3 Procedure 
The workshop was advertised on the NIN website, and the announcement was distributed widely 
among the NIN partners and collaborators, and beyond.  Registration was open to all who could demonstrate 
that they are active in the field of nanosafety, nanotoxicology, nanobiology or related.  In order to ensure that 
the discussions were manageable, participation was on a first-come-first-served basis and was limited to 60 
participants.  
In each session the topic was introduced by two plenary lectures followed by a general discussion in 
two randomly generated groups.  Discussions during the workshop were structured into four specific 
sessions, as described in Table 1.  The discussions were guided by a number of pre-defined questions and 
managed by an appointed chair. The chairs were assisted by rapporteurs who were appointed to prepare a 
report (including the major discussion points). The rapporteurs’ reports, as well as the summaries of 
presentations from the plenary lectures, were used as the foundation for this report (see annex 1 for list of 
speakers and the titles of their presentations).  The authors of the present report include the chairs, 
rapporteurs and presenters from the workshop.   
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Table 1 – Topic areas covered during the Workshop. 
 Discussion topic 
Session 1 Are there data we are certain of, that could be the basis of a comparative testing 
approach? 
 
Is there an emerging direction that offers real promise that we could focus on? 
 
Are there pitfalls that should definitely be avoided? 
 
Session 2 Can we make nanosafety/nanotoxicology a quantitative science? 
 
Can we identify new end-points to investigate? How can these be incorporated into 
OECD testing? 
 
Is high-throughput screening a viable way forward? 
 
Session 3 Within the research arena of human health effects, are there certain aspects where we 
(EU, NIN team members) are world-leading (niche areas – e.g. the protein corona)? 
 
Are there known pitfalls in protocols/ experiments that should definitely be avoided? 
 
Should we focus on validation of new methodologies or the refinement of existing 
metrologies for nanomaterials? 
 
How should we progress with the topic of biological system characterization? 
 
Session 4 How can we best gather the existing protocols and standard operating procedures 
(SOPs)  from all sources and cross-validate them? 
 
Are reference standard materials for specific biological end-points (positive and 
negative control NMs) a real possibility when batch-to-batch variability of NMs is so 
high? 
 
How can NIN optimally contribute to existing efforts (OECD, ISO, IAHN etc.)? 
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4 Results 
4.1 Session 1: Key points to build upon from existing state-of-the-art 
An important element of NIN is to coordinate research findings from the ongoing EU projects in which its 
partner organisations are engaged, in order to ensure that the knowledge gained is transferred into other 
projects in an appropriate manner.  Thus, the aim of the first session was to highlight some key findings from 
ongoing / ending EU projects, as the basis for future progress. Presentations from the EU projects 
NanoTransport and NanoInteract were given, focussing on the experiences of these projects (“lessons 
learned”) as well as the  current state of the art in nanosafety evaluation. 
The initial discussions following these presentations centred on occupational exposure, and it was 
highlighted that the existing occupational exposure threshold limit values are not specific to ENMs and that 
many of the existing studies have significant limitations, as it is not possible at present to measure all of the 
relevant parameters for determining occupational exposure to ENMs.  It was highlighted that measurement 
methods employed in determining occupational exposure need to be routinely calibrated with recognised and 
appropriately sized reference materials.   
It was widely agreed that more than one measurement technique should be employed to determine 
the size distribution of ENMs; however these techniques need to be chosen and optimised for each specific 
NM sample. The (U.S.) National Institute of Standards and Technology (NIST) has a list of sizes determined 
with specific techniques (including dynamic light scattering (DLS), atomic force microscopy (AFM), and 
electron microscopy (EM)) for one particular reference material, where some significant variation in the 
reported size emerged depending on the technique used.7  Correct sample shipping, storing, handling and 
preparation were all highlighted as being key elements to ensure successful size measurements: the issues 
of shipment and storage conditions of ENMs, as well as the time required for shipping have to be accounted 
forby researchers to ensure that NMs are stored in the correct environment and only used for the 
manufacturer’s specified lifetime, which will be dependant on the specific reference material.  Additionally, 
the measurement technique and its inherent assumptions need to be are reported together with the size data 
in publications. This was deemed necessary for the reporting of all stages of sample testing from both a 
metrological and biological viewpoint; detailed descriptions should be provided to aid inter-laboratory 
reproducibility. 
Next the discussion focused on biological endpoints, and an attempt was made to identify the most 
suitable technology/protocol(s) available to determine different endpoints such as cell viability, Reactive 
Oxygen Species production and others. The discussion focused on trying to define a test method which 
could give inter-laboratory reproducibility. It was widely agreed that to do this a set of complementary tests 
needed to be established.  Genotoxicity studies were identified as a possible candidate for comparison with 
cell viability results, as a first round-robin study using the Comet assay has already been performed 
successfully.8 Again it was noted that the endpoint used for viability measurements needed to be free from 
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absorptive interferences (the case of Single Walled Carbon Nanotubes (SWCNTs) interfering with 
colorimetric assays was highlighted9) and perhaps alternative endpoints such as colony forming assays 
should be employed.10 It was suggested that toxicity should also be assessed in a more mechanistic 
approach, using for example confocal and electron microscopies as these approaches would provide 
information regarding the morphological changes that may occur following exposure of ENMs to cells, 
helping further to elucidate the possible mechanism(s) of toxicity. 
Selection of the types of cell lines/cultures employed in assessing impacts of NMs also needs careful 
consideration: to enable in vitro experiments to potentially be extrapolated to human exposure the 
recommendation was made that a variety of different cell types be studied, (epithelial, endothelial, 
macrophages etc.) and that co-culture models be established and validated. The mechanisms of NMs uptake 
may also be affected by the cell type employed in the study. Furthermore the stage of the cell lifecycle was 
noted to be of importance (confluence levels, proliferation rates etc.) as this will play a role in the interactions 
of ENMs with cells, and on the observed effects. 
In a more general approach, the type, source and content of protein supplements employed in 
cellular experiments was noted to play a significant role in the generation of inter-laboratory differences. A 
suggestion was made that researchers explore different types of protein supplements (e.g. Foetal Bovine 
Serum (FBS), Bovine Serum Albumin (BSA)) to try and reduce/overcome this problem of variation, and to 
define a standard protein supplement for comparative cell culture experiments (taking into account that 
different cells need different environments). It was further highlighted that the attachment time of a protein to 
NMs is extremely rapid (coverage by abundanat proteins within milliseconds, with rearrangements occurring 
over several hours11), indicating that the ENMs will be coated in a biological material during the assay 
andthat this needs to be considered as a contributing factor to the resultant measurement outcome. 
In terms of identifying priority biological testing protocols, a number of endpoints were agreed upon 
by the discussion group (see below). However, the lack of standardised methods (protocols, SOPs) was 
identified as a limiting factor. It was widely agreed that the degree of calibration required for successful 
physical and chemical experiments would also need to be implemented in biological assays for successful 
impact assessment of NMs. The following biological endpoints were agreed as being optimal markers for 
cellular nanotoxicology: 
  Reactive Oxygen Species (ROS) Screening 
  Cytotoxicity (Viability, Proliferation, Morphological Studies) 
  Genotoxicity 
  Cellular Signalling 
The discussion identified a variety of problems associated with ENMs that are not applicable to their bulk 
counterparts.  Again it was highlighted that in order to assess the nano-scale effect, adequate controls must 
be incorporated into the experiment. Such controls could include parallel testing of the NMs bulk counterpart 
and nano form to assess the nano (size / curvature) effect, testing of the molecular oir ionic form of the 
material, where available, and consideration of the possibility that the ENMs adsorb to their surface enzymes 
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released by the cell following ENMs-cell interactions.  A further point was made that the experimental 
endpoints employed in all studies need to be validated and assessed for correct operation, and to ensure 
that the presence of the ENMs does not interfere with the readout.  Again, the case of SWCNT was noted as 
an example in which significant interference has been observed for a variety of cytotoxic endpoints.  A final 
note was made on the testing of ENMs: it is vital that researchers ensure that the ENMs they seek to test are 
actually in the nanoparticulate form in the test system, by continually monitoring the dispersion state of the 
particles at all stages of the experiment 
Software and hardware differences were also identified as a source of inter-laboratory variability and 
the establishment of standardised protocols may not necessarily resolve all issues associated with the 
testing of NMs, but it was felt that such an approach would significantly aid in the development of the area. 
. 
4.2 Session 2: Reference materials – Are other approaches needed? 
In this session, presentations were given on the topic of the current progress in terms of the development of 
standard and reference NMs. Most of the materials that are used as standard and/or reference materials in 
toxicity testing are industrial materials (e.g. carbon black, P25 titanium dioxide), and are mostly agglomerates 
rather than individually dispersed (monodisperse) ENMs. While these reflect the majority of the materials as 
currently available, they might not be suitable for all purposes that reference materials are required for.   
During the presentations on reference materials, several different types and uses of reference materials 
were identified, as described in Table 2.  The distinction between calibrants and matrix reference materials 
was made, whereby a calibrant is used for the quantitative step in a measurement process, while a matrix 
reference material is used for quality control of the full analytical process, including sample preparation, as it 
is considered to be more representative of the “real” experimental situation or end-use application.   
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Table 2: The different types of reference materials and their uses. 
Reference Material (RM) A material that is sufficiently homogeneous and stable with respect to one 
or more specific properties which has been established to be fit for its 
intended use in measurement.  RMs can be used as size calibrants for 
example, to calibrate instruments for size determination. 
Note: RMs are typically produced by chartered bodies such as Institute for 
Reference Materials and Measurements (IRMM) or National Institute of 
Standards and Technology, but may also be provided by commercial 
entities often with traceability to formally certified RMs. 
Certified Reference Material 
(CRM) 
An RM accompanied by a certificate providing the value of the specified 
property, its associated uncertainly and stating the metrological 
traceability. 
Note: CRMs are typically developed by chartered bodies such as IRMM or 
NIST. 
Quality Control Materials Reference materials without a certificate and without a property value 
having an uncertainty small enough for use in calibration. This is typically 
the class of reference materials used during in-house method validation 
exercises, for interlaboratory comparisons for method assessment, etc. 
Study or Test Material A well-characterized material that is provided from a single source for use 
in studies (tests) designed to test a hypothesis or explore a specific 
material attribute across one or more testing labs. RMs could serve this 
purpose, but more likely this material would be procured or manufactured 
for a limited use and for a limited time frame that is not generally 
compatible with RM or CRM development. 
Benchmarks (controls) Materials that express a desired property and are sufficiently 
homogeneous and stable to be used as a marker for that property when 
incorporated into experimental studies. Benchmarks typically would have 
stability measured in years or decades and be widely accessible; it may 
not be necessary for a benchmark to have an associated or certified 
property value. RMs could serve as benchmarks and controls. An 
important criterion for this type of standard material is broad acceptance by 
the research community.  Any useful benchmark or control material must 
be a reference material (at least sufficiently homogeneous and stable for 
its intended use) to be useful. 
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Uses for reference materials were identified as follows: 
- calibration or qualification of analytical instruments (certified value of the reference material should 
be traceable) (Note: (metrological) traceability is the property of a value, not of a material, and is to 
be distinguished from the material traceability throughout its production – also called trackability.) 
- validation of methods and procedures 
- manufacturing quality control 
- inter-laboratory comparisons and laboratory accreditation 
- biological studies (e.g., NIST distributes gold NP RMs that can be used to conjugate chains to, in 
order to manipulate the physico-chemical properties in a highly controllable manner) 
- benchmarks (e.g. used as positive (biological) controls; need to be fully characterized, with agreed 
dispersion protocol and a reproducible biological end-point, e.g. genotoxicity). 
It is important to note that the intended use determines the choice of which type of reference material is 
needed. From the presentations, the list of available (and forthcoming) reference NMs that emerged is 
shown in Table 3.  
Table 3: The list of reference NMs currently available or in preparation at IRMM or NIST (as of June 2008). 
Nanomaterial type Available sizes Supplier 
Silica 40 nm IRMM 
Gold 10, 30, 60 nm NIST 
In preparation: 
Bimodal Silica  IRMM 
Single-walled carbon nanotubes  NIST 
Titanium dioxide (TiO2) 
nanopowder (industrial) 
25 nm NIST 
Future considerations: 
Pure phase dispersible TiO2 < 25 nm, companion to industrial 
grade RM 
NIST 
Conjugated or functionalised Gold  Prototype development stage NIST 
Silver Currently undergoing feasibility 
study. 
NIST 
Cerium oxide Still assessing need and 
applications 
NIST 
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It was recognized by all that developing reference materials is a laborious (and costly) task, and that 
currently limited budgets are available for this task.  A suggestion emerged that it could be useful to have 
some workshops on defining what reference materials would be needed and with what priority – e.g. for 
upcoming FP7 projects.  To some extent this has already been attempted in Europe through the Department 
of the Environment, Food and Rural Affairs (DEFRA) funded REFNANO project,12 and in the U.S. as part of 
an National Nanotechnology Initiative (NNI)-sponsored workshop held at NIST in September 2007.13 It is 
essential that further workshops are performed in this area, taking into consideration of the ongoing efforts, 
and building on these efforts..  Additionally, as many industrial materials are agglomerated / aggregated, the 
need for well characterized agglomerates / aggregates was highlighted, and the question raised as to the 
possibility to produce, store and ship agglomerates / aggregates as reference materials. In addition, the need 
for polymeric reference ENMs (e.g. capsules, dendrimers) was highlighted.  
The discussion also covered to the topic of whether there is a need for standardized dispersion 
media and standardised dispersion protocols to be supplied with reference materials.  As different tests 
require different dispersion media, it was suggested that it would be most useful if a consensus on three or 
four representative dispersion media could be reached.  The National Iinstitute for Occupational Safety and 
Health (NIOSH) have developed a simulated lung fluid which showed excellent promise as a dispersion 
medium,14 although other studies have shown that lung surfactants cannot break up TiO2 agglomerates.15 In 
one study of NM exposure to mice, a very encouraging outcome was demonstrated using bronchoalveolar 
lavage (BAL) fluid instead of blood serum to disperse the ENMs.16  However, it was pointed out that 
simulated lung fluids are very dilute, whereas when the “stabilized” ENMs are introduced into the lungs in 
vivo they come in contact with a very concentrated system which can induce immediate agglomeration / 
aggregation.  Additionally, the small number of components in lung fluids may not be able to reproduce the 
complexity of the situation in blood.  It was suggested that for in vivo studies, the best practice was to first 
disperse the NMs in BAL-fluid, then in medium (including supplements such as serum, antibiotics etc.)) prior 
to exposure studies.  However, the broader application of BAL-fluid as a generic dispersing medium for 
studies beyond the original intended use requires further investigation.   
A discussion on standard endpoints is currently underway, co-ordinated by the OECD. The need for 
transparent and open discussion with OECD was emphasized. The possibility of identifying new toxicological 
end-points, that should be incorporated in the OECD test list was also discussed. Also risk assessment, 
behavioral effects and chronic endpoints from a health perspective could be very relevant, however, it was 
considered that for the moment, disease-based endpoints might be too complicated.  Interaction of NMs with 
proteins and other biological molecules is not on the OECD NM characterisation list. This can be raised at 
the relevant committees, and perhaps could be a unique focal point for NIN. It was noted that molecular 
toxicology is rarely directly attributable to the level of proteins, and as such identification of protein binding 
alone is unlikely to be sufficient to characterise / predict potentail toxicological impacts of ENMs.  
Included in the potential “new” endpoints was the suggestion of protein fibrillation.17, 18 Fibrillation as 
an end-point has recently been highlighted as an issue to watch by the Scientific Committee on Emerging 
and Newly Identified Health Risks (SCENIHR) Opinion on Risk Assessment of Products of 
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Nanotechnology.19 However, the opinion also mentions that neurodegeneration research is still at an early 
stage, and it is unclear as yet whether it is relevant for humans or should be a cause for concern.   
OECD is actively assessing the appropriateness of the current standard protocols for the risk 
assessment of ENMs, and are looking to the scientific community for support in this process.  A challenge for 
NIN could be to assess the validity and relevance of the OECD list of endpoints and protocols, and to identify 
ones that are of particular interest for NIN participants.  The OECD list is included as Annex II in the report, 
and the tests of particular relevance to the issues discussed at the workshop are highlighted.  
 
4.3 Session 3: Protocols for in vitro and in vivo experiments 
In this session, presentations were given on the topics of the key requirements / issues for (i) in vitro 
studies, (ii) quantitative in vivo studies, and (iii) biological system characterization.  Important issues 
highlighted included the need to provide precise information relating to the exact concentrations applied in 
experiments, as well as the optimal dose metric to use (µg/cm2 or µg/mL or both).  The importance of 
studying biokinetics was also discussed, as such investigations can provide essential information regarding 
dose-estimates in specific organs of interest, and a rational basis for toxicological studies (at relevant doses).  
It was concluded that a combination of both macro and microscopic dosimetric analysis will significantly 
advance the current ‘state-of-the-art’ analytical technique(s). 
Subsequent discussions centred on identification of key areas where NIN can advance the state-of-
the-art in the assessment of the effects of ENMs on human health and safety.  From this it emerged that NIN 
could address issues related to sharing details of experimental procedures, and development of methods to 
close current knowledge gaps.  While it was agreed that the NIN network, indeed the area as a whole, is not 
at the stage of developing SOPs there are protocols established in research groups, laboratories and even 
micro-networks within NIN.  These protocols, while ad hoc and used primarily to cross-validate results from 
different laboratories, could be shared with the wider network via the NIN website. This would allow others in 
the network to learn from the wider community, as would also serve to confirm and validate (and improve 
where necessary) the protocols.  Since the time of the workshop, NIN has indeed established such a portal 
for internal use initially (www.nanoimpactnet.eu).  Once the protocols have been peer-reviewed by NIN 
members, and thus become more robust and generally accepted by the NIN community they will be made 
publicly available.  An important aspect of this knowledge and protocol sharing network will include reporting 
on the success, or failure, of a protocol, due to the open access nature of the protocol sharing aspect in NIN 
which allows protocols to be edited and improved, ensuring that other researchers can be aware of any 
limitations and/or problems associated with the protocol(s). 
Comparison with other fields of research were made, such as protein expression and cell biology, in 
which if a member clones a protein or engineers a cellular transcript, they are obliged to make it available to 
others in the area. It was suggested that NIN should operate in a similar fashion such that results and 
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protocols are available throughout the consortium.  In addition, the members may also have cell lines or 
cultures they wish to share and/or may wish others to confirm a particular set of results - such details could 
also be included on the NIN website.  WP1 (Human Hazards and Exposure) and WP5 (Integration, 
Nomenclature and ELSI) will collaborate to ensure that this is implemented 
Considerable time was devoted to the discussion of the pitfalls of (nano)toxicology research.  With 
respect to improving reproducibility of cell culture, the network needs to share procedural knowledge in 
particular regarding the choice of cells. Many cells used in toxicology studies are tumour cells because of 
ease of handling, low time requirements for the cells to reach confluence and low costs. Nevertheless, these 
cells can undergo significant phenotypical and genotypical changes which are not being taken into 
consideration in the interpretation of nanotoxicity studies.  However, moving away from such cells could 
cause difficulties in procedure development, as primary cells are significantly harder to culture, are more 
sensitive to additives in the media, and could increase the overall number of variables, thereby decreasing 
comparability across studies.  To develop robust procedures with a high degree of credibility it was 
recommended that cell lines which are readily available and traceable, i.e. same source and commercially 
available, should be used rather than specifically isolated / modified cell lines.  It was also highlighted that 
commercially purchased cells / cell lines come with strict protocols for their culture.  Depending on the cell 
line, data sheets/ test sheets are available from the supplier. However the cell line characterization is crucial 
and should be reported and included in any data for publication. 
Generally, impurities in the NMs also need to be characterised/ studied as their toxic effects can be 
severe with the NMs potentially acting as carriers for the impurities, leading to possible contamination of the 
cell culture and heightened toxicity. 
 
4.4 Session 4: Worldwide and round-robin approaches 
A very interesting presentation on stakeholder needs in terms of Nano Environmental Health and Safety 
(EHS) introduced this session.  It was clear from the presentation that there is currently limited toxicology 
data that corresponds with exposure to ENMs and their potential exposure routes, and that current testing 
protocols do not correlate with acute and/or chronic effects.  It is imperative therefore, that industry 
acknowledges this pitfall and defines the constituents of the ENMs and how these (may) related to the 
toxicity of the ENMs. An additional point that was raised was the need for validated procedures for ENM 
handling, such as their shipping, sampling, exposure and disposal.  Furthermore, the possibility of learning 
from studies on non-human models, such as invertebrates, via cross-reading or correlation of data was also 
discussed as an important  key step, once validated tests that correlate in vitro effects with in vivo effects 
have been developed and implemented.  Currently, dosmetric data research has reported extrapolation from 
in vitro to in vivo, as well as extrapolation of data gained from various laboratory animals and humans.  At 
this time however, there is no such data in regards to (nano)toxicology research.  
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The discussion resulting from this session centred on whether NIN can share protocols and data with 
the OECD and if so what are the mechanisms other then peer-reviewed publication of results in the open 
scientific literature.  The point was made that OECD is a broad body with considerable tasks before them 
beyond nanotechnology. They are therefore looking to others to provide relevant data and they will deliver 
the strong administrative process to reinforce the results and conclusions found from the data.   
It was suggested that NIN could be considered as one of the very early stages in the process used 
by the ISO and OECD, as could other similar networks where these issues are debated and eventually 
published.  However, it was noted that realistically OECD, ISO, ASTM and other regulatory bodies need to 
eventually take control of the process. This is also the approach recommended by a recent workshop on 
Enabling Standards for Nanomaterial Characterization held at NIST in October 2008, and co-sponsored by 
several U.S. federal agencies (report pending). 
The conclusion from the discussion was that the various bodies such as the OECD could / should 
provide templates for the type of data and documents that are required to progress this field, and could also 
provide some training workshops with respect to the process necessary for standard and method 
development, such that these can be built into the protocols that are emerging within the scientific 
community.  NIN could certainly be a vehicle to facilitate this, via one of its training schools. 
An additional (unexpected) benefit  of the meeting was that it presented a nice opportunity for 
members of the International Alliance on NanoEHS Harmonisation (IANH, www.nanoehsalliance.org) to 
meet and to obtain an update on the most relevant issues, which helped them to finalize their workplan 
before going public during the Nanotoxicology conference in September 2009.  
5 Conclusions and Recommendations 
A number of conclusions and recommendations emerged from the workshop.   The main conclusions are 
listed below (in order of discussion).  No priority or ranking has been applied to this list. 
  The importance of sharing experiences was highlighted, along with the need for closer cooperation 
between ongoing and future projects.  The lack of validation of existing test methods and the added 
complication that ENMs can affect the test performance was highlighted as the baseline for further 
discussions. 
  Cell culture work can have a number of pitfalls which need to be reported and procedures or protocols 
need to be adhered to strictly.  All reports and publications should include a section on the cell line 
characterisation (passage (division) number, phenotype confirmation, etc.). 
   ENMs can act as carriers of contaminants or impurities which can impact on the cellular responses.  
Thus, reports and publications should also include sufficient repeats and controls, and checks for 
endotoxin impurities or other contaminants such as catalysts, surfactants etc. should be conducted and 
reported as standard. 
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  There is an urgent need for reference NMs not just for calibration of physical and chemical 
measurements, but also as positive and negative controls for various measurement methods assessing 
biological impacts.  
   Details of protocols and open knowledge should appear on the website with access to all NIN members 
to help develop a structured approach to method development – this has since been implemented within 
the NIN project in line with the deliverable set-out by the NIN consortium. 
   OECD and other international organisations are working on a list of end-points for assessing ENMs. 
Within the discussions specific end-points were highlighted as being advantageous for ‘round-robin’ 
studies, to validate the tests and to generate data regarding a range of endpoints for an expansive panel 
of ENMs.  Examples of endpoint specific areas discussed are genotoxicity, oxidative stress and cell 
viability. 
   Additional end-points, not yet in the OECD list were also highlighted, including ENM interaction with 
biomolecules, and ENM-induced protein fibrillation. 
   Generally it was agreed that the OECD and ISO are approachable and are interested in close 
collaboration in order to ascertain a ‘knowledge-base’ for all ENMs. NIN should therefore, act as a 
vehicle to tie all EU projects together and contributing credible and valid data to the OECD process.   
  Thus, it was recommended that NIN track all communications and develop closer links with other ongoing 
and future projects who are willing to share details on ENMs testing. This would allow NIN to be in a 
position within the scientific community to make a valid representation and contribution to existing efforts 
by the OECD and other organisational bodies, such as ISO. 
   It was recommended that OECD could / should provide templates for the type of data and documents 
that they require and also provide some training workshops in respect of the process necessary for 
standard and method development, culminating in a ‘knowledge-base’ of standard and methodological 
protocols for use within the scientific community.  NIN could facilitate this, via its training schools. 
   The need for another workshop on this topic closer to the end of the NIN project was highlighted, as 
clearer consensus of the best practices, and recommendations regarding which protocols for which end-
point should be significantly further advanced by then.  Additionally, a second workshop would enable us 
to reflect on the role of NIN in facilitating the onward development and framing of the field of assessment 
of the human health impacts of ENMs.  
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Annex 1: List of speakers and titles of their presentations 
 
NanoImpactNet WP1 Workshop 
Hosted by University College Dublin, Ireland; 20th June 2008 
 Workshop on Standardization of materials and protocols 
Day-chair: University College Dublin 
08:30- 09:00 Registration and coffee  
09:00- 09:05 Welcome Michael Riediker 
09:05- 09:20 Aims and goals  
o Why do we need standards and protocols? 
o Are round-robin approaches a viable approach 
Kenneth Dawson 
09:20- 11:10 
09:20-09:35 
09:35-09:50 
09:50-11.00 
 
Session 1 – Existing EU activities on standardisation 
NanoTransport outcomes and future perspectives 
NanoInteract – dispersion, cell culture standards, protocols 
Discussion: Key points to build upon from existing state-of-the-
art 
 
Qinglan Wu 
Iseult Lynch 
All participants 
11:00- 11:20 Coffee  
11:20- 13:20 
11:20- 11:35 
11:35- 11:50 
11:50- 13.00 
 
Session 2 – Standard materials 
EU efforts towards reference materials 
NIST activities on materials standardisation 
Discussion: Other approaches needed? 
 
Gert Roebben 
Vince Hackley 
All participants 
13:00- 14:00 Lunch  
14:00- 16:00 
14:00- 14:15 
14:15- 14:30 
 
14:30- 15:30 
Session 3 – Protocols for in vitro and in vivo experiments 
Key requirements / issues for in vitro studies  
Key requirements for quantitative in vivo studies 
Discussion: Key areas NIN can advance state-of-the-art 
 
Jean-Pierre Kaiser 
Wolfgang Kreyling 
All participants 
15:30-  16:30 Coffee  
16:30- 18:00 
16:30- 16:50 
 
16:50- 17:50 
 
Session 4 – Worldwide and round-robin approaches 
Needs for NanoEHS research from an industrial perspective 
including the need for standard test methodologies, etc. 
Discussion: Next steps in standardization for nanosafety 
 
Mike Garner 
 
All participants 
17:50- 18:00 Concluding remarks and end of meeting Kenneth Dawson 
Michael Riediker 
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Annex 2 – OECD activities in determining minimum 
physicochemical characteristics 
The OECD report on the list of manufactured materials and list of endpoint for phase one of the OECD 
testing programme20 describes the initial set of parameters that should be characterised. According to 
the report, addressing this set should help ensure consistency between the various tests to be carried 
out on specific NMs and should lead to the development of dossiers for each ENM describing basic 
characterization, fate, ecotoxicity and mammalian toxicity information. 
It is expected that the list of endpoints be refined based on the practical results obtained 
through the testing programme. As such, phase one testing is expected to be of an exploratory nature, 
science-based and without any consequences for existing regulatory datasets. 
The list of OECD endpoints is given below, exactly as laid out in the OECD report.  In this list, 
the ones that are considered of particular importance, based on the discussions from the present 
workshop are highlighted.  
 
Endpoints 
Nanomaterial Information/Identification  
• Nanomaterial name (from list) 
• CAS Number 
• Structural formula/molecular structure 
• Composition of nanomaterial being tested (including degree of purity, known impurities or additives) 
• Basic morphology 
• Description of surface chemistry (e.g., coating or modification) 
• Major commercial uses 
• Known catalytic activity 
• Method of production (e.g. precipitation, gas phase) 
 
Physical-Chemical Properties and Material Characterization  
• Agglomeration/aggregation 
• Water solubility 
• Crystalline phase 
• Dustiness 
• Crystallite size 
• Representative TEM picture(s) 
• Particle size distribution 
• Specific surface area 
• Zeta potential (surface charge) 
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• Surface chemistry (where appropriate) 
• Photocatalytic activity 
• Pour density 
• Porosity 
• Octanol-water partition coefficient, where relevant 
• Redox potential 
• Radical formation potential 
• Other relevant information (where available) 
 
Environmental Fate  
• Dispersion stability in water 
• Biotic degradability 
• Ready biodegradability 
• Simulation testing on ultimate degradation in surface water 
• Soil simulation testing 
• Sediment simulation testing 
• Sewage treatment simulation testing 
• Identification of degradation product(s) 
• Further testing of degradation product(s) as required 
• Abiotic degradability and fate 
• Hydrolysis, for surface modified nanomaterials 
• Adsorption- desorption 
• Adsorption to soil or sediment 
• Bioaccumulation potential 
• Other relevant information (when available) 
 
Environmental Toxicology  
• Effects on pelagic species (short term/long term) 
• Effects on sediment species (short term/long term) 
• Effects on soil species (short term/long term) 
• Effects on terrestrial species 
• Effects on microorganisms 
• Other relevant information (when available) 
 
Mammalian Toxicology  
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• Pharmacokinetics (ADME) 
• Acute toxicity 
• Repeated dose toxicity 
If available: 
• Chronic toxicity 
• Reproductive toxicity 
• Developmental toxicity 
• Genetic toxicity 
• Experience with human exposure 
• Other relevant test data 
 
Material Safety  
Where available: 
• Flammability 
• Explosivity 
• Incompatibility 
 
